Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 464 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Tomorrow is National Prescription Drug Take-Back Day! April 29, 2022 ESMO Asia Congress 2022, 2-4 December 2022 November 17, 2022 New Research Discovers How Scalp Cooling Helps Chemo Patients Keep Their... February 6, 2021 What’s happened to cancer clinical trials during the COVID-19 pandemic? November 4, 2020 Load more HOT NEWS Tesco is making it even easier to support life-saving research Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use [ESMO... Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side...
